Skip to main content

Table 2 Comparison of seroprevalence of hepatitis B virus (HBV) markers by different age and vaccine type received in infancy

From: Hepatitis B virus vaccination booster does not provide additional protection in adolescents: a cross-sectional school-based study

Age group Vaccine type Plasma-derived Recombinant Total P-value
  Items     
15 y/o N [birth cohort] 410 [1989–91] 886 [1993–97] 1296  
  anti-HBs (+), n 177 307 484 0.004*
  (%, 95% CI) (43.2, 38.4-48.0) (34.7, 31.6-37.8) (37.3, 34.3-39.9)  
  anti-HBs (−), n 233 579 812  
  (%, 95% CI) (56.8, 52.0-61.6) (65.3, 62.2-68.4) (62.7, 60.1-65.3)  
  HBsAg (+), n 7 6 13 0.129
  (%, 95% CI) (1.7, 0.4-3.0) (0.7, 0.2-1.2) (1.0, 0.5-1.5)  
  HBsAg (−), n 403 880 1283  
  (%, 95% CI) (98.3, 97.0-99.6) (99.3, 98.8-99.8) (99.0, 98.5-99.5)  
18 y/o N [birth cohort] 2575 [1987–91] 1295 [1993–94] 3870  
  anti-HBs (+), n 1184 529 1713 0.003*
  (%, 95% CI) (46.0, 44.1-47.9) (40.8, 38.1-43.5) (44.3, 42.7-45.9)  
  anti-HBs (−), n 1391 766 2157  
  (%, 95% CI) (54.0, 52.1-55.9) (59.2, 56.5-61.9) (55.7, 54.1-57.3)  
  HBsAg (+), n 40 10 50 0.049*
  (%, 95% CI) (1.6, 1.1-2.1) (0.8, 0.3-1.3) (1.3, 0.9-1.7)  
  HBsAg (−), n 2535 1285 3820  
  (%, 95% CI) (98.4, 97.9-98.9) (99.2, 98.7-99.7) (98.7, 98.3-99.1)  
  1. Note: anti-HBs, antibody to HBV surface antigen; HBsAg, HBV surface antigen; y/o, year old; Data are presented as or n and percentage.
  2. *p-value < 0.05 was considered statistically significant after test.